13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001710065
Total reported value
—
—
1 檔
—
The Q2 2026 SEC filing reveals that AJU IB Investment Co., Ltd. held a total portfolio value of —, covering 1 public equity positions.
In Q2 2026, AJU IB Investment Co., Ltd. adopted a defensive or profit-taking posture, trimming 0 positions and completely liquidating 6 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Ikena Oncology Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx Inc | — | EXIT | Sold out |
| 2 | KYMR | Kymera Therapeutics Inc | — | EXIT | Sold out |
| 3 | SEER | Seer Inc | — | EXIT | Sold out |
| 4 | RLYB | Rallybio CORP | — | EXIT | Sold out |
| 5 | STRO | Sutro Biopharma, Inc. | — | EXIT | Sold out |
| 6 | XLO | Xilio Therapeutics Inc | — | EXIT | Sold out |
| 7 | ✓ | Ikena Oncology Inc | — | — | Unchanged |
According to official SEC Form 13F filings, AJU IB Investment Co., Ltd. reported a total U.S. public equity portfolio value of — across 1 disclosed positions in Q2 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top Position Liquidated / Trimmed
ACLXGBX
前期市值: $25.7M
During Q2 2026, AJU IB Investment Co., Ltd.'s top holdings by market value included IKENA ONCOLOGY INC (0.0%). The largest single position, IKENA ONCOLOGY INC, represented 0.0% of total portfolio value.
In Q2 2026, AJU IB Investment Co., Ltd. made 6 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.